Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022

Rhea-AI Summary

Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on March 1, 2022, at 8:30 a.m. ET to discuss its Q4 2021 and full-year results, along with a general business update. Investors can join by calling 844-277-9450 for domestic or 336-525-7139 for international access, referencing conference ID 6277858. The event will also be available for live streaming on their website. Seres' SER-109 program achieved positive clinical results and has received FDA Breakthrough Therapy and Orphan Drug designations, targeting recurrent C. difficile infection.

Positive

• SER-109 achieved positive pivotal clinical results.
• Received FDA Breakthrough Therapy and Orphan Drug designations.
• Potential to become a first-in-class microbiome therapeutic.

Negative

• None.

 

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 1, 2022 at 8:30 a.m. ET to discuss fourth quarter and full year 2021 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6277858. To join the live webcast, please visit the “Investors and Media” section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to reduce the recurrence of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to prevent bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients.

For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005039/en/

PR

Kristin Ainsworth

kainsworth@serestherapeutics.com

IR

Carlo Tanzi, Ph.D.

ctanzi@serestherapeutics.com

Source: Seres Therapeutics, Inc.

FAQ

When is the Seres Therapeutics conference call for Q4 2021 results?

The conference call will take place on March 1, 2022, at 8:30 a.m. ET.

What is the conference ID for the Seres Therapeutics call?

The conference ID number is 6277858.

What therapeutic programs are being evaluated by Seres Therapeutics?

Seres is evaluating SER-301 in ulcerative colitis and SER-155 in patients receiving allogeneic stem cell transplants.

What designations has SER-109 received from the FDA?

SER-109 has received Breakthrough Therapy and Orphan Drug designations from the FDA.

What disease is SER-109 targeting?

SER-109 aims to reduce the recurrence of C. difficile infection.